These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18644649)

  • 1. Acute rejection of non-functional allograft in kidney transplant recipients with hepatitis C treated with peginterferon-alpha 2a.
    Sperl J; Petrasek J; Spicak J; Viklicky O
    J Hepatol; 2008 Sep; 49(3):461-2; author reply 462-3. PubMed ID: 18644649
    [No Abstract]   [Full Text] [Related]  

  • 2. Peginterferon alpha-2b and acute allograft failure in a heart transplant recipient.
    Wang BY; Chang HH; Chen IM; Shih CC; Yang AH
    Ann Thorac Surg; 2010 May; 89(5):1645-7. PubMed ID: 20417802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: case study.
    Fabrizi F; D'Ambrosio R; Pallotti F; Berardinelli L; Messa P; Martin P; Aghemo A
    Int J Artif Organs; 2014 Nov; 37(11):803-8. PubMed ID: 25362901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute hepatitis C infection in a renal transplant recipient: primacy of the liver or kidney?
    Althaf MM; Abdelsalam MS; Rashwan M; Nadri Q
    BMJ Case Rep; 2014 Jun; 2014():. PubMed ID: 24907214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peginterferon- and ribavirin-induced bipolar episode successfully treated with lamotrigine without discontinuation of antiviral therapy.
    Navinés R; Castellví P; Solà R; Martín-Santos R
    Gen Hosp Psychiatry; 2008; 30(4):387-9. PubMed ID: 18585548
    [No Abstract]   [Full Text] [Related]  

  • 6. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin.
    Fried MW; Jensen DM; Rodriguez-Torres M; Nyberg LM; Di Bisceglie AM; Morgan TR; Pockros PJ; Lin A; Cupelli L; Duff F; Wang K; Nelson DR
    Hepatology; 2008 Oct; 48(4):1033-43. PubMed ID: 18697207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug effects and pegylation.
    Wooten JM
    South Med J; 2011 Feb; 104(2):83-4. PubMed ID: 21206333
    [No Abstract]   [Full Text] [Related]  

  • 8. [Sarcoidosis associated with the treatment of hepatitis C: case report and Spanish literature review].
    Trullàs JC; Hernández-Marcet P; Bisbe J
    Med Clin (Barc); 2011 May; 136(14):649-50. PubMed ID: 21051060
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of hepatitis C in patients on renal replacement therapy].
    Tornai I; Mátyus J
    Orv Hetil; 2007 Mar; 148(11):489-94. PubMed ID: 17350920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Secondary hemophagocytic syndrome due to Peg-interferon administration].
    Ruiz Ramos J
    Farm Hosp; 2014 Jan; 38(1):73-4. PubMed ID: 24483865
    [No Abstract]   [Full Text] [Related]  

  • 11. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials.
    Chalasani N; Manzarbeitia C; Ferenci P; Vogel W; Fontana RJ; Voigt M; Riely C; Martin P; Teperman L; Jiao J; Lopez-Talavera JC;
    Hepatology; 2005 Feb; 41(2):289-98. PubMed ID: 15660392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral nervous system involvement in a haemodialysis patient treated with pegylated interferon.
    Ruiz-Fuentes MC; Rubert-Gómez De Quero A; De Gracia-Guindo C; Galindo-Sacristán P; Osuna-Ortega A
    Nefrologia; 2012; 32(6):863-5. PubMed ID: 23169385
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatitis C treatment, HAART and side effects.
    TreatmentUpdate; 2001; 13(7):7-8. PubMed ID: 11794865
    [No Abstract]   [Full Text] [Related]  

  • 14. Peginterferon alfa-2a (40KD): a potent long-acting form of interferon alfa-2a for the treatment of hepatitis C.
    Modi MW; Lamb MW; Shiomi M
    Adv Exp Med Biol; 2003; 519():59-67. PubMed ID: 12675208
    [No Abstract]   [Full Text] [Related]  

  • 15. Interferon for hepatitis C patients with psychiatric disorders.
    Asnis GM; De La Garza R; Rego SA; Henderson MA; Reinus JF
    Am J Psychiatry; 2004 Dec; 161(12):2332; author reply 2332-4. PubMed ID: 15569920
    [No Abstract]   [Full Text] [Related]  

  • 16. Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts.
    Wéclawiack H; Kamar N; Mehrenberger M; Guilbeau-Frugier C; Modesto A; Izopet J; Ribes D; Sallusto F; Rostaing L
    Nephrol Dial Transplant; 2008 Mar; 23(3):1043-7. PubMed ID: 17913730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of peginterferon and interferon in treating Chinese patients with chronic hepatitis C.
    Zhao S; Liu E; Yu H; Yang H; Xun M; Xue X; Song J; Xu K; Chu Y
    Hepatogastroenterology; 2008; 55(84):1047-54. PubMed ID: 18705326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients.
    Teta D; Lüscher BL; Gonvers JJ; Francioli P; Phan O; Burnier M
    Nephrol Dial Transplant; 2005 May; 20(5):991-3. PubMed ID: 15741205
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy.
    Sikole A; Dzekova P; Selja N; Gaseva M; Nikolov IG; Zabzun M; Muharemi S; Asani A; Amitov V; Mena S; Grunevska V; Ivanovski L; Polenakovic M
    Ren Fail; 2007; 29(8):961-6. PubMed ID: 18067041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.